Primary PCI in Patients With ST-elevation Myocardial Infarction and Multivessel Disease: Treatment of Culprit Lesion Only or Complete Revascularization
Launched by RIGSHOSPITALET, DENMARK · Oct 9, 2013
Trial Information
Current as of April 26, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the best treatment approach for patients who have a type of heart attack called ST-elevation myocardial infarction (STEMI) along with blockages in multiple blood vessels (this is known as multivessel disease). The researchers want to find out whether treating just the main blockage (the culprit lesion) or treating all blockages in the heart (complete revascularization) leads to better outcomes for the patients.
To be eligible for this trial, participants need to be at least 18 years old and have experienced chest pain for less than 12 hours with specific heart test results that show a serious heart issue. They should also have at least one major blockage in a blood vessel and other significant blockages in the heart. Participants in the trial will receive treatment based on the study's findings, and they will be monitored closely to see how well they do after the procedure. It’s important to note that certain individuals, such as those who are pregnant or have severe bleeding disorders, cannot participate in this trial.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years.
- • Acute onset of chest pain of \< 12 hours' duration.
- • ST-segment elevation ≥ 0.1 millivolt in ≥ 2 contiguous leads, signs of a true posterior infarction or documented newly developed left bundle branch block.
- • Culprit lesion in a major native vessel.
- • MVD (non-culprit vessels with angiographic stenosis \>50%)
- • Successful primary PCI
- Exclusion Criteria:
- • Pregnancy.
- • Known intolerance of acetylsalicylic acid, clopidogrel, heparin or contrast.
- • Inability to understand information or to provide informed consent.
- • Haemorrhagic diathesis or known coagulopathy.
- • Stent thrombosis
- • Significant left main stem stenosis
- • Cardiogenic shock at admittance
About Rigshospitalet, Denmark
Rigshospitalet, located in Copenhagen, Denmark, is one of the leading hospitals in Scandinavia and a prominent center for clinical research and innovation. As a key academic institution affiliated with the University of Copenhagen, Rigshospitalet is dedicated to advancing healthcare through rigorous clinical trials and groundbreaking research across various medical disciplines. The hospital’s commitment to excellence is reflected in its multidisciplinary approach, collaboration with international research networks, and focus on improving patient outcomes through evidence-based practices. With state-of-the-art facilities and a team of highly qualified professionals, Rigshospitalet plays a crucial role in translating scientific discoveries into effective treatments and therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Copenhagen, , Denmark
Aalborg, , Denmark
Aalborg, Region Northern Jutland, Denmark
Patients applied
Trial Officials
Steffen Helqvist, MD, DMSci
Study Chair
Rigshospitalet, University of Copenhagen, Denmark
Thomas Engstrøm, MD, DMSci
Principal Investigator
Rigshospitalet, University of Copenhagen, Denmark
Henning Kelbæk, MD. DMSci
Principal Investigator
Rigshospitalet, University of Copenhagen, Denmark
Lars Køber, MD, Prof., DMSci
Principal Investigator
Rigshospitalet, University of Copenhagen, Denmark
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials